BRIEF-Aveo announces proposed offering of common stock
March 28, 2017 at 06:36 AM EDT
* Aveo Pharmaceuticals- offering's proceeds to be used in development, pre-commercial expenses incurred for ongoing phase 3 clinical trial of tivozanib Source text for Eikon: Further company coverage:
